Biotechnology Drugs Set To Get Cheaper

The high cost of biotechnology drugs has been pinching the public and biotechnology companies realizing this are making an effort towards making these products more affordable. Here are some of the examples which would make you believe what I am saying. Amgen has announced that that it would be limiting out of pocket expenses for the patient for its colorectal drug, Vectibix to five percent of their annual incomes whereas recently Genentech announced that it would be limiting the costs for its cancer treatment to $55,000 annually. I think that it is a welcome step and it would certainly go a long way in increasing the popularity of biotechnology.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>